ASP Isotopes Inc. 8-K

What Happened
On June 25, 2026, ASP Isotopes Inc. (ASPI) and ENDRA Life Sciences Inc. issued a joint press release announcing a proposed merger of Noble Africa LLC (a wholly‑owned ASPI subsidiary and intermediate holding company for Renergen Limited) with a subsidiary of ENDRA, with Noble Africa to continue as the surviving entity. The press release also states Noble Africa has entered into subscription agreements with certain accredited investors, qualified institutional buyers and non‑U.S. persons for a private placement expected to result in approximately $50 million of gross proceeds. The press release is attached to ASPI’s Form 8‑K as Exhibit 99.1 (Item 7.01; Form 8‑K filed June 25, 2026).

Key Details

• Filing date: June 25, 2026 (Form 8‑K, Items 7.01 and 9.01).
• Transaction: Proposed merger of Noble Africa LLC with a subsidiary of ENDRA; Noble Africa to be the surviving entity.
• Financing: Subscription agreements in place for a private placement into Noble Africa expected to raise ~ $50 million in gross proceeds.
• Disclosure: Joint press release attached as Exhibit 99.1 and incorporated by reference.

Why It Matters
This filing notifies investors of a material corporate transaction (a proposed merger) affecting ASPI’s wholly‑owned subsidiary and a contemporaneous financing commitment expected to bring significant capital (~$50M) into that subsidiary. Investors should watch for subsequent filings with details on definitive merger agreements, closing conditions, use of proceeds, and any impacts on ASPI’s consolidated financial condition or ownership structure.